Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742079 · ClinicalTrials.gov registry record · Phase 4
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT00742079: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00742079 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00742079, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study will examine whether pretreatment with D-cycloserine before cognitive behavioral therapy can reduce impairments still present in people with stable cases of schizophrenia as well as determine which traits make schizophrenics most likely to respond to D-cycloserine treatment.
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy
- DRUG D-cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00742079
The ClinicalTrials.gov registry entry for NCT00742079 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cognitive Behavioral Therapy is the first listed.
NCT00742079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00742079 about?
NCT00742079 is a clinical study titled "Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia". This study will examine whether pretreatment with D-cycloserine before cognitive behavioral therapy can reduce impairments still present in people with stable cases of schizophrenia as well as determine which traits make schizophrenics most likely to respond to D-cycloserine treatment.
What is the current status of trial NCT00742079?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2006-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00742079?
The interventions under investigation include: Cognitive Behavioral Therapy (BEHAVIORAL), D-cycloserine (DRUG).
Who is sponsoring clinical trial NCT00742079?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.